CFGS
BLPH

Concourse Financial Group Securities’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Concourse Financial Group Securities’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-40
Closed -$258 – 2486
2023
Q1 		$315 Buy
+40
New +$139 ﹤0.01% 2279

Other funds holding BLPH

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Concourse Financial Group Securities's BLPH Position: Q2 2023 in Review

Concourse Financial Group Securities sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2023, closing a stake of 40 shares — an estimated $258 sold.

Concourse Financial Group Securities first reported a position in BLPH in Q1 2023 and held it in 1 quarter. The position peaked at $315 in Q1 2023. 23 funds tracked by Wall St. Rank hold BLPH as of Q2 2023.

  • Concourse Financial Group Securities reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Concourse Financial Group Securities sold 40 Bellerophon Therapeutics, Inc. shares in Q2 2023, an estimated $258.
  • Concourse Financial Group Securities first reported a position in Bellerophon Therapeutics, Inc. in Q1 2023 and held it in 1 quarter.
  • Concourse Financial Group Securities's Bellerophon Therapeutics, Inc. position peaked at $315 in Q1 2023.
  • 23 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2023.

Based on Concourse Financial Group Securities's 13F filing for Q2 2023, filed 10 Aug 2023.